Search

Your search keyword '"Panchal, Anesh"' showing total 17 results
Start Over Author "Panchal, Anesh"
17 results on '"Panchal, Anesh"'

1. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Author

Seymour, John F., Kipps, Thomas J., Eichhorst, Barbara F., D'Rozario, James, Owen, Carolyn J., Assouline, Sarit, Lamanna, Nicole, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Mellink, Clemens, Chyla, Brenda, Panchal, Anesh, Lu, Tong, Wu, Jenny Q., Jiang, Yanwen, Lefebure, Marcus, Boyer, Michelle, and Kater, Arnon P.

Published
2022
Full Text
View/download PDF

3. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study

Author

Al-Sawaf, Othman, primary, Zhang, Can, additional, Lu, Tong, additional, Liao, Michael Z., additional, Panchal, Anesh, additional, Robrecht, Sandra, additional, Ching, Travers, additional, Tandon, Maneesh, additional, Fink, Anna-Maria, additional, Tausch, Eugen, additional, Schneider, Christof, additional, Ritgen, Matthias, additional, Böttcher, Sebastian, additional, Kreuzer, Karl-Anton, additional, Chyla, Brenda, additional, Miles, Dale, additional, Wendtner, Clemens-Martin, additional, Eichhorst, Barbara, additional, Stilgenbauer, Stephan, additional, Jiang, Yanwen, additional, Hallek, Michael, additional, and Fischer, Kirsten, additional

Published
2021
Full Text
View/download PDF

4. Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Author

Morschhauser, Franck, primary, Carlo-Stella, Carmelo, additional, Dickinson, Michael, additional, Phillips, Tycel, additional, Houot, Roch, additional, Offner, Fritz, additional, Haioun, Corinne, additional, Corradini, Paolo, additional, Hutchings, Martin, additional, Sureda, Anna, additional, Martínez-López, Joaquín, additional, Wrobel, Tomasz, additional, Wu, Shang-Ju, additional, Lundberg, Linda, additional, Mulvihill, Estefania, additional, Perez-Callejo, David, additional, Relf, James, additional, Panchal, Anesh, additional, Humphrey, Kathryn, additional, and Bachy, Emmanuel, additional

Published
2021
Full Text
View/download PDF

5. Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study

Author

Ghosh, Nilanjan, primary, Townsend, William, additional, Dickinson, Michael, additional, Topp, Max, additional, Tani, Monica, additional, Santoro, Armando, additional, Crump, Michael, additional, Morschhauser, Franck, additional, Le Gouill, Steven, additional, Mehta, Amitkumar, additional, Panchal, Anesh, additional, Wu, Chun, additional, Barrett, Martin, additional, Humphrey, Kathryn, additional, Qayum, Naseer, additional, and Hutchings, Martin, additional

Published
2021
Full Text
View/download PDF

6. Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Author

Hutchings, Martin, primary, Sureda, Anna, additional, Terol, María José, additional, Bosch Albareda, Francesc, additional, Corradini, Paolo, additional, Larsen, Thomas Stauffer, additional, Rueda Dominguez, Antonio, additional, Panchal, Anesh, additional, Bottos, Alessia, additional, Carlile, David, additional, Wang, Yanjie, additional, Filézac De L'Étang, Audrey, additional, Tandon, Maneesh, additional, Sellam, Gila, additional, and Gritti, Giuseppe, additional

Published
2021
Full Text
View/download PDF

7. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study

Author

Al-Sawaf, Othman, Zhang, Can, Lu, Tong, Liao, Michael Z., Panchal, Anesh, Robrecht, Sandra, Ching, Travers, Tandon, Maneesh, Fink, Anna-Maria, Tausch, Eugen, Schneider, Christof, Ritgen, Matthias, Boettcher, Sebastian, Kreuzer, Karl-Anton, Chyla, Brenda, Miles, Dale, Wendtner, Clemens-Martin, Eichhorst, Barbara, Stilgenbauer, Stephan, Jiang, Yanwen, Hallek, Michael, Fischer, Kirsten, Al-Sawaf, Othman, Zhang, Can, Lu, Tong, Liao, Michael Z., Panchal, Anesh, Robrecht, Sandra, Ching, Travers, Tandon, Maneesh, Fink, Anna-Maria, Tausch, Eugen, Schneider, Christof, Ritgen, Matthias, Boettcher, Sebastian, Kreuzer, Karl-Anton, Chyla, Brenda, Miles, Dale, Wendtner, Clemens-Martin, Eichhorst, Barbara, Stilgenbauer, Stephan, Jiang, Yanwen, Hallek, Michael, and Fischer, Kirsten

Abstract

PURPOSE The CLL14 study has established one-year fixed-duration treatment of venetoclax and obinutuzumab (Ven-Obi) for patients with previously untreated chronic lymphocytic leukemia. With all patients off treatment for least three years, we report a detailed analysis of minimal residual disease (MRD) kinetics and long-term outcome of patients treated in the CLL14 study. PATIENTS AND METHOD Patients were randomly assigned to receive six cycles of obinutuzumab with 12 cycles of venetoclax or 12 cycles of chlorambucil (CIb-Obi). Progression-free survival (PFS) was the primary end point. Key secondary end points included rates of undetectable MRD and overall survival. To analyze MRD kinetics, a population-based growth model with nonlinear mixed effects approach was developed. RESULTS Of 432 patients, 216 were assigned to Ven-Obi and 216 to CIb-Obi. Three months after treatment completion, 40% of patients in the Ven-Obi arm (7% in the CIb-Obi arm) had undetectable MRD levels < 10(-6) by next-generation sequencing in peripheral blood. Median MRD doubling time was longer after Ven-Obi than CIb-Obi therapy (median 80 v 69 days). At a median follow-up of 52.4 months, a sustained significant PFS improvement was observed in the Ven-Obi arm compared with CIb-Obi (median not reached v 36.4 months; hazard ratio 0.33; 95% CI, 0.25 to 0.45; P < .0001). The estimated 4-year PFS rate was 74.0% in the Ven-Obi and 35.4% in the CIb-Obi arm. No difference in overall survival was observed (hazard ratio 0.85; 95% CI, 0.54 to 1.35; P = .49). No new safety signals occurred. CONCLUSION Appearance of MRD after Ven-Obi is significantly slower than that after CIb-Obi with more effective MRD reduction. These findings translate into a superior long-term efficacy with the majority of Ven-Obi-treated patients remaining in remission. (C) 2021 by American Society of Clinical Oncology

Published
2021

9. The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib

Author

O’Sullivan, Jennifer M., primary, Hamblin, Angela, additional, Yap, Christina, additional, Fox, Sonia, additional, Boucher, Rebecca, additional, Panchal, Anesh, additional, Alimam, Samah, additional, Dreau, Helene, additional, Howard, Kieran, additional, Ware, Pauline, additional, Cross, Nicholas C. P., additional, McMullin, Mary Frances, additional, Harrison, Claire N., additional, and Mead, Adam J., additional

Published
2019
Full Text
View/download PDF

10. A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL: dual mTORC1/2 inhibition in relapsed, refractory DLBCL

Author

Eyre, Toby, Hildyard, Catherine, Hamblin, Angela, Ali, Ayesha, Houlton, Aimee, Hopkins, Louise, Royston, Daniel, Linton, Kim, Pettitt, Andrew, Rule, Simon, Cwynarski, Kate, Barrington, Sally, Warbey, Victoria, Wrench, David, Barrans, Sharon, Hirst, Caroline, Panchal, Anesh, Roudier, Martine, Harrington, Elizabeth, Davies, Andrew, and Collins, Graham

Abstract

Patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) who are unfit for or relapsed post autologous stem‐cell transplantation have poor outcomes. Historically, mTORC1 inhibitors have produced responses in approximately 30% of patients in this setting. mTORC1 inhibitor efficacy may be limited by resistance mechanisms including AKT activation by mTORC2. To date, dual mTORC1/2 inhibitors targeting both the TORC1 and TORC2 complexes have not been investigated in DLBCL. This phase II trial investigated the oral dual mTORC1/2 inhibitors vistusertib in an intermittent dosing schedule of 125 mg b.d. for two days per week. Thirty patients received vistusertib and six received vistusertib‐rituximab for up to six cycles (28‐day cycles). Two partial responses were achieved on monotherapy. Duration of response were 57 and 62 days respectively for these patients. 19% had stable disease within six cycles. In the monotherapy arm, the median progression‐free survival was 1.69 (95% confidence interval 1.61‐2.14) months and median overall survival was 6.58 (95% CI 3.81‐not reached) months respectively. The median duration of response or stable disease across the trial duration was 153 days (95% confidence interval 112‐not reached). Tumour responses according to PET/CT versus CT were concordant. There were no differences noted in tumour volume response according to cell of origin by either gene expression profiling or immunohistochemistry. Vistusertib +/‐ rituximab was well tolerated; across 36 patients 86% of adverse events were grade (G) 1‐2. Common vistusertib‐related adverse events were similar to those described with mTORC1 inhibitors: nausea (47% G1‐2), diarrhoea (27% G1‐2, 6% G3), fatigue (30% G1‐2, 3% G3), mucositis (25% G1‐2, 6% G3), vomiting (17% G1‐2) and dyspepsia (14% G1‐2). Dual mTORC1/2 inhibitors do not clearly confer an advantage over mTORC1 inhibitors in relapsed or refractory DLBCL. Potential resistance mechanisms are discussed within.

Published
2019

11. CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Author

Hutchings, Martin, primary, Gritti, Giuseppe, additional, Sureda, Anna, additional, Terol, Maria Jose, additional, Dyer, Martin JS, additional, Iacoboni, Gloria, additional, Townsend, William, additional, Bacac, Marina, additional, Bröske, Ann-Marie E, additional, Dimier, Natalie, additional, Ferlini, Cristiano, additional, Keelara, Abiraj, additional, Lahr, Angelika, additional, Lechner, Katharina, additional, Moore, Tom, additional, Morcos, Peter N, additional, Panchal, Anesh, additional, Weisser, Martin, additional, and De Vriendt, Ciel, additional

Published
2019
Full Text
View/download PDF

12. A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL

Author

Eyre, Toby A., primary, Hildyard, Catherine, additional, Hamblin, Angela, additional, Ali, Ayesha S., additional, Houlton, Aimee, additional, Hopkins, Louise, additional, Royston, Daniel, additional, Linton, Kim M., additional, Pettitt, Andrew, additional, Rule, Simon, additional, Cwynarski, Kate, additional, Barrington, Sally F., additional, Warbey, Victoria, additional, Wrench, David, additional, Barrans, Sharon, additional, Hirst, Caroline S., additional, Panchal, Anesh, additional, Roudier, Martine P., additional, Harrington, Elizabeth A., additional, Davies, Andrew, additional, and Collins, Graham P., additional

Published
2019
Full Text
View/download PDF

13. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial

Author

Tan, Wei Shen, primary, Panchal, Anesh, additional, Buckley, Laura, additional, Devall, Adam J., additional, Loubière, Laurence S., additional, Pope, Ann M., additional, Feneley, Mark R., additional, Cresswell, Jo, additional, Issa, Rami, additional, Mostafid, Hugh, additional, Madaan, Sanjeev, additional, Bhatt, Rupesh, additional, McGrath, John, additional, Sangar, Vijay, additional, Griffiths, T.R. Leyshon, additional, Page, Toby, additional, Hodgson, Dominic, additional, Datta, Shibendra N., additional, Billingham, Lucinda J., additional, and Kelly, John D., additional

Published
2019
Full Text
View/download PDF

14. Longitudinal Mutational Analysis in Hydroxycarbamide-Resistant/Intolerant Essential Thrombocythemia Treated on the Majic-ET Study

Author

O'Sullivan, Jennifer, primary, Hamblin, Angela, additional, Panchal, Anesh, additional, Yap, Christina, additional, Fox, Sonia, additional, Alimam, Samah, additional, Dreau, Helene Marie-Pierre, additional, Howard, Kieran, additional, Ware, Pauline, additional, Baker, Samantha, additional, Cross, Nicholas C.P., additional, McMullin, Mary Frances, additional, Harrison, Claire N., additional, and Mead, Adam J., additional

Published
2018
Full Text
View/download PDF

15. Correlation Between Treatment Outcomes, Baseline Characteristics and Molecular Responses in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Essential Thrombocythemia

Author

Harrison, Claire N., primary, Mead, Adam, additional, Fox, Sonia, additional, Panchal, Anesh, additional, Yap, Christina, additional, Houlton, Aimee E, additional, Aliman, Samah, additional, Ewing, Joanne C, additional, Wood, Marion, additional, Chen, Frederick, additional, Coppell, Jason, additional, Panoskaltsis, Nicki, additional, Knapper, Steven, additional, Ali, Sahra, additional, Hamblin, Angela, additional, Scherber, Robyn M., additional, Geyer, Holly, additional, Scotch, Allison H, additional, Dueck, Amylou Constance, additional, Cross, Nicholas CP, additional, Mesa, Ruben A., additional, and McMullin, Mary Frances, additional

Published
2016
Full Text
View/download PDF

16. A Phase II Study to Determine the Safety and Efficacy of the Dual m-TORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination with Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Author

Eyre, Toby A., Hildyard, Catherine, Panchal, Anesh, Houlton, Aimee E, Hopkins, Louise, Hamblin, Angela, Linton, Kim, Pettitt, Andrew, Rule, Simon, Cwynarski, Kate, Barrington, Sally, Wrench, David, Davies, Andrew, and Collins, Graham

Abstract

Background

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results